The effect of two different doses of Magnesium Sulfate on prevention of pain during Etomidate injection

Comparison of two different doses of Magnesium Sulfate on the prevention of pain during Etomidate injection

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20090129001615N6

Enrollment

Registered

2023-02-21

Start date

2023-09-11

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain due to Etomidate injection.

Interventions

Intervention 1: Intervention group 1: injection of 750 mg of magnesium sulfate 30 seconds before the injection of etomidate. Intervention 2: Intervention group 2: injection of 1 gram of magnesium sulf

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. All patients who need to anesthesia With Etomidate Aged 18-65 years with ASA (American Society of Anesthesiologists) grade:1 or 2 2. No History of allergy to Magnesium 3. candidate for Elective Surgery

Exclusion criteria

Exclusion criteria: 1. Patients with neuromuscular disease 2. Patients who have Difficulty Communicating 3. Myocardial Ischemia 4. Cardiac Arrhythmia 5. Seizure 6. Endocrine and Metabolic Diseases 7. Mental Disorders 8. Severe Neurological Disease 9. People without a vein in the back of the hand 10. Pregnancy 11. Liver and kidney diseases 12. Thrombophlebitis 13. Chronic pain 14. pancreatic disorders 15. Patients receiving sedative or analgesic drugs 16. Substance abusers

Design outcomes

Primary

Measure	Time frame
Pain intensity during Etomidate injection. Timepoint: Every minute until 10 minutes after Etomidate injecting. Method of measurement: Pain intensity is evaluated with using a 4-point Likert scale including: 0=no pain, 1=mild (pain expressed in response to the patient's question and without symptoms), 2=moderate (pain expressed in response to the patient's question) can be expressed along with the symptoms of the disease or pain spontaneously without asking the patient), 3=severe (a strong facial response or a response accompanied by arm withdrawal or facial grimacing) is measured.	—

Measure

Time frame

Pain intensity during Etomidate injection. Timepoint: Every minute until 10 minutes after Etomidate injecting. Method of measurement: Pain intensity is evaluated with using a 4-point Likert scale including: 0=no pain, 1=mild (pain expressed in response to the patient's question and without symptoms), 2=moderate (pain expressed in response to the patient's question) can be expressed along with the symptoms of the disease or pain spontaneously without asking the patient), 3=severe (a strong facial response or a response accompanied by arm withdrawal or facial grimacing) is measured.

—

Secondary

Measure	Time frame
Blood pressure. Timepoint: Every minute after Etomidate injection up to 10 minutes. Method of measurement: Pulse oximeter.;Heart rate. Timepoint: Every minute after Etomidate injection up to 10 minutes. Method of measurement: Pulse oximeter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzim Honarmand

Esfahan University of Medical Sciences

honarmand@med.mui.ac.ir+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026